Clinical trials: Ventilator Acquired Pneumonia
Ventilator Associated Pneumonia
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB
- Trial name
- NCT05685615
- Testing
- BV100 plus Polymyxin B, BAT
- Where
- 16 sites in Georgia, Greece and 1 more
- Volunteers
- 39 people
- Sponsor
- BioVersys AG
Ventilator-Associated Pneumonia (VAP)
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of…
- Trial name
- NCT01853982
- Testing
- Ceftolozane/Tazobactam, Piperacillin/Tazobactam
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 4 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP
Reporting patterns and results of initial antibiotic treatment in patients with complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP) including…
- Conditions
- Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and, Nosocomial Pneumonia (NP)
- Trial name
- RECOMMEND (NCT02364284)
- Where
- 27 sites in Brazil, France and 4 more
- Volunteers
- 1,322 people
- Sponsor
- Pfizer
Ventilator Associated Pneumonia, Staphylococcus Aureus
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
- Trial name
- SAATELLITE-2 (NCT05331885)
- Testing
- Suvratoxumab
- Where
- 27 sites in Belgium, France and 4 more
- Volunteers
- 24 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex…
- Trial name
- NCT06746883
- Testing
- Non-interventional
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Innoviva Specialty Therapeutics
Pneumonia, Bacterial, Nosocomial Infection
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
The purpose of this study is to assess the safety and effectiveness of doripenem treatment among Filipino patients with nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infection.
- Conditions
- Pneumonia, Bacterial, Nosocomial Infection, Intraabdominal Infections, Urinary Tract Infection
- Trial name
- NCT01763008
- Testing
- No intervention
- Where
- 4 sites in Philippines
- Volunteers
- 170 people
- Sponsor
- Janssen Pharmaceutica
Pneumonia, Bacterial Pneumonia
An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
The purpose of this study is to evaluate the effectiveness and safety of doripenem monohydrate in the treatment of patients with nosocomial (hospital-acquired) pneumonia.
- Conditions
- Pneumonia, Bacterial Pneumonia, Ventilator-Associated Pneumonia, Infections, Nosocomial
- Trial name
- NCT00502801
- Testing
- doripenem
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 185 people
- Sponsor
- PriCara, Unit of Ortho-McNeil, Inc.
Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types…
- Conditions
- Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia
- Trial name
- NCT04882085
- Testing
- Zavicefta, Ceftazidime-Avibactam, Best Available Treatment
- Where
- 37 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Ventilator Associated Pneumonia
Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia
The purpose of this research study is to measure the levels of ceftobiprole in the blood, urine and tissues of the lungs during and after administration of four doses of ceftobiprole. Safety of the drug will also be evaluated.
- Trial name
- NCT00771719
- Testing
- Ceftobiprole
- Volunteers
- 1 people
- Sponsor
- Basilea Pharmaceutica
Pneumonia, Ventilator-Associated
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
Given the challenges of treating complex cases of VAP caused by P. aeruginosa and K. pneumoniae, TechnoPhage developed a bacteriophage cocktail (TP-122) against those pathogens, aiming to provide a hospital-based add-on therapy…
- Trial name
- RECOVER (NCT06370598)
- Testing
- TP-122A
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Technophage, SA
Pneumonia
Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.), along with another drug called an aminoglycoside (a different type of antibiotic) is effective in decreasing or reducing the rate of…
- Trial name
- NCT00050401
- Testing
- MERREM I.V. 2g as a 3 hour infusion every 8 hours, vancomycin I.V. 1 g every 12 hours, tobramycin I.V. 5 mg/kg every 24 hours
- Where
- 10 sites in United States
- Volunteers
- 500 people
- Sponsor
- Pfizer
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
This is a Phase 3, randomized, double-blind, multicenter, comparative study evaluating cefepime-zidebactam (FEP-ZID) versus ceftazidime-avibactam (CAZ-AVI) with or without colistin in the treatment of adults with…
- Trial name
- NCT07885891
- Testing
- Cefepime-Zidebactam, Ceftazidime-avibactam with or without Colistin
- Where
- 55 sites in Bosnia and Herzegovina, Bulgaria and 12 more
- Volunteers
- 324 people
- Sponsor
- Wockhardt
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Ventilator-Associated Pneumonia
To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia
The purpose of this study is to show that doripenem is as effective as imipenem-cilastatin in the treatment of patients with ventilator-associated pneumonia.
- Trial name
- NCT00589693
- Testing
- Doripenem, Imipenem-Cilastatin
- Where
- 100 sites in United States, Argentina and 19 more
- Volunteers
- 274 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pseudomonas Aeruginosa, Ventilator Associated Pneumonia
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen that rarely causes disease in healthy people, but is a significant problem for critically ill or immunocompromised individuals.
- Trial name
- NCT00691587
- Testing
- KB001
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Humanigen, Inc.
Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
This is a phase 3, multicenter, prospective, randomized study of intravenous (IV) ceftolozane/tazobactam versus IV meropenem in the treatment of adult participants with either ventilator-associated bacterial pneumonia (VABP) or…
- Conditions
- Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases
- Trial name
- ASPECT-NP (NCT02070757)
- Testing
- Ceftolozane/tazobactam, Meropenem
- Volunteers
- 726 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate…
- Trial name
- NCT06801223
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Innoviva Specialty Therapeutics
Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are to assess the safety, tolerability, and pharmacokinetics (PK) of cefiderocol after single-dose administration in hospitalized pediatric participants 3 months to < 12 years of age with…
- Conditions
- Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
- Trial name
- NCT04215991
- Testing
- Cefiderocol, Standard of Care
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 91 people
- Sponsor
- Shionogi
Critical Illness, Enteral Nutrition
Optimizing Enteral Nutrition Regimen for Critically Ill Patients
Clinical Trial The goal of this clinical trial is to learn whether different enteral feeding cycles (18-hour, 20-hour, or standard 24-hour continuous feeding) improve outcomes for critically ill ICU patients who need tube…
- Conditions
- Critical Illness, Enteral Nutrition, Ventilator Associated Pneumonia, Hyperglycemia
- Trial name
- NCT07270939
- Testing
- 20-Hour Cycled Enteral Nutrition with a 4-Hour Fasting Window, 18-Hour Cycled Enteral Nutrition with a 6-Hour Fasting Window
- Volunteers
- 150 people
- Sponsor
- Hamad Medical Corporation
Ventilator Associated Pneumonia
Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated Patients Using the AnapnoGuard System
Ventilator Associated Pneumonia (VAP) is a common complication experienced by mechanically ventilated patients and within the framework of Respiratory Intensive Care Units.
- Trial name
- NCT01126320
- Testing
- AnapnoGuard 100,, routine mechanical ventilator
- Where
- Israel
- Volunteers
- 161 people
- Sponsor
- Hospitech Respiration